January 6, 2015 – San Diego, CA
FDA issues it’s strongest warning discouraging the use of laparoscopic power morcellation for removal of uterus or uterine fibroids. Use can increase the risk of developing cancer!
The FDA has discouraged the use of laparoscopic power morcellation for removal of uterus or uterine fibroids.
It’s been estimated by the FDA that 1 in 350 women having a hysterectomy or myomectomy for the treatment of fibroids is found to have an unsuspected uterine sarcoma, a type of uterine cancer that includes leiomyosarcoma. Overall it is estimated that 650,000 women will have a myomectomy or hysterectomy for the management of symptomatic uterine fibroids.
According to Martin Hood, managing attorney for Hood National Law Group, “Doctors had every right to rely on minimally invasive surgical procedures such as laparoscopic uterine power morcellation in treatment for uterine fibroids.”
For women with symptomatic uterine fibroids the promise of removing fibroid tissue through small incisions is preferable to cutting through the abdominal wall. The recovery time for these women is much shorter and less painful.
Unfortunately this procedure which basically slices up the fibroid tissue into tiny pieces for removal may also spread cancerous tissue throughout the body. Patients need to become aware of this risk, and the FDA is waking up to that need to warn women who may be considering this form of surgery.
Finding out if you are eligible for a large settlement for your morcellator injury is 100% free, fast and easy by filling out our Morcellator Compensation Form.